Vicore Pharma AB

Quick facts

Phase 3 pipeline

• C21 · Oncology
  C21 is a CD40 agonist that activates the CD40 receptor on immune cells to enhance anti-tumor immune responses.

Phase 2 pipeline

• Buloxibutid · Other

Phase 1 pipeline

• C106 solution

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Vicore Pharma AB portfolio CI brief
• Vicore Pharma AB pipeline updates RSS